Rheumatic Immune-Related AEs With Immune Checkpoint Inhibitors More Severe Than Previously Reported

TUESDAY, Sept. 22, 2026-- For patients receiving immune checkpoint inhibitors (ICIs), rheumatic immune-related adverse events (rh-irAEs) are usually moderate or severe, with more than one-third leading to permanent ICI discontinuation, according...